Cargando…

Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients

Malignant gastrointestinal stromal tumours (GIST) have a poor prognosis. Since these tumours are resistant to conventional radiation and chemotherapy, surgery has been the mainstay of treatment. However, surgery is usually inadequate for the treatment of malignant GIST. Imatinib, a KIT tyrosine kina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bümming, P, Andersson, J, Meis-Kindblom, J M, Klingenstierna, H, Engström, K, Stierner, U, Wängberg, B, Jansson, S, Ahlman, H, Kindblom, L-G, Nilsson, B
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2003
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394385/ https://www.ncbi.nlm.nih.gov/pubmed/12888812 http://dx.doi.org/10.1038/sj.bjc.6600965

Ejemplares similares

Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Laparoscopic resection of locally advanced gastrointestinal stromal tumour (GIST) of the stomach following neoadjuvant imatinib chemoreduction
por: Berney, Christophe R.
Publicado: (2015)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy
por: Vassos, Nikolaos, et al.
Publicado: (2021)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Characterizing gastrointestinal stromal tumors and evaluating neoadjuvant imatinib by sequencing of endoscopic ultrasound-biopsies
por: Hedenström, Per, et al.
Publicado: (2017)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Role of imatinib in the management of early, operable, and advanced GI stromal tumors (GISTs)
por: Vetto, John T
Publicado: (2009)

Rapidly progressive dyspnea in gastrointestinal stromal tumor (GIST) with imatinib cardiac toxicity
por: Ghias, Adnan Asif Parvez, et al.
Publicado: (2018)

Reducing uncertainty in health-care resource allocation
por: Simonsson, T, et al.
Publicado: (2007)

Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
por: Bussabawalai, Thanaporn, et al.
Publicado: (2019)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment
por: Deshaies, Isabelle, et al.
Publicado: (2010)

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018)

Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
por: Boichuk, Sergei, et al.
Publicado: (2018)

SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib
por: Chen, Yan, et al.
Publicado: (2022)

A mutation-based radiomics signature predicts response to imatinib in Gastrointestinal Stromal Tumors (GIST)
por: Cappello, Giovanni, et al.
Publicado: (2023)

Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis
por: Liu, Zhen, et al.
Publicado: (2022)

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study
por: Joensuu, H, et al.
Publicado: (2011)

Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST)
por: Mahadevan, Daruka, et al.
Publicado: (2014)

Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib
por: Werewka-Maczuga, Agnieszka, et al.
Publicado: (2017)

Symptoms reported by gastrointestinal stromal tumour (GIST) patients on imatinib treatment: combining questionnaire and forum data
por: den Hollander, Dide, et al.
Publicado: (2022)

Effect of skeletal muscle loss during neoadjuvant imatinib therapy on clinical outcomes in patients with locally advanced GIST
por: Ding, Ping’an, et al.
Publicado: (2022)

Optimizing Adherence to Adjuvant Imatinib in Gastrointestinal Stromal Tumor
por: Tetzlaff, Eric D., et al.
Publicado: (2013)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Prevalence of Germline Mutations in Patients with Pheochromocytoma or Abdominal Paraganglioma and Sporadic Presentation: A Population-Based Study in Western Sweden
por: Muth, Andreas, et al.
Publicado: (2012)

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
por: Wu, Ting-Jung, et al.
Publicado: (2006)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

Spontaneous Non-Traumatic Mediastinal Hematoma in a Patient on Imatinib Therapy for a Gastrointestinal Stromal Tumor (GIST)
por: Aziz, Rida, et al.
Publicado: (2023)

Treatment of gastrointestinal tumor (GIST) of the rectum requiring abdominoperineal resection following neoadjuvant imatinib: a cost-effectiveness analysis
por: Farid, Mohamad, et al.
Publicado: (2020)

Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST): Coincidence or a Real Phenomenon
por: Saif, Muhammad Wasif, et al.
Publicado: (2019)

The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.
por: Wängberg, B., et al.
Publicado: (1991)

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2012)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_up872vgnpgvi1jqs6gojsettcv